Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC).

by Susanne Brakemeier, Lars Vogt, Lisa Adams, Bianca Zukunft, Gerd Diederichs, Bernd Hamm, Klemens Budde, Marcus R Makowski
Published 2017-01-01

Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept

by Mira Choi, Friederike Bachmann, Kaiyin Wu, Nils Lachmann, Danilo Schmidt, Susanne Brakemeier, Michael Duerr, Andreas Kahl, Kai-Uwe Eckardt, Klemens Budde, Peter Nickel
Published 2020-08-01

Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR).

by Susanne Brakemeier, Wolfgang Arns, Frank Lehner, Oliver Witzke, Oliver Vonend, Claudia Sommerer, Anja Mühlfeld, Thomas Rath, Robert Schuhmann, Bianca Zukunft, Irena Kroeger, Martina Porstner, Klemens Budde
Published 2019-01-01

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients

by Michael Duerr, Eva V. Schrezenmeier, Lukas J. Lehner, Léon Bergfeld, Petra Glander, Stephan R. Marticorena Garcia, Christian E. Althoff, Ingolf Sack, Susanne Brakemeier, Kai-Uwe Eckardt, Klemens Budde, Fabian Halleck
Published 2019-02-01

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.

by John J Bissler, J Chris Kingswood, Elzbieta Radzikowska, Bernard A Zonnenberg, Elena Belousova, Michael D Frost, Matthias Sauter, Susanne Brakemeier, Petrus J de Vries, Noah Berkowitz, Maurizio Voi, Severine Peyrard, Klemens Budde
Published 2017-01-01